Loading provider…
Loading provider…
Gynecologic Oncology Physician in Morgantown, WV
NPI: 1174727770Primary Practice Location
WEST VIRGINIA UNIVERSITY HOSPITALS, INC
1 Medical Center Dr, Morgantown, WV
Primary Employer
University Health Associates
wvumedicine.org
HQ Phone
Get MD Kristy's Phone NumberMobile
Get MD Kristy's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTX State Medical License
TX State Medical License
FL State Medical License
WV State Medical License

American Board of Obstetrics and Gynecology
Gynecologic Oncology
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 23 | 30 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 22 | 33 |
Using Social Marketing Theory as a Framework for Understanding and Increasing HPV Vaccine Series Completion Among Hispanic Adolescents: A Qualitative Study.
Authors: Angelica Roncancio, Kristy Ward, Chakema Carmack, Becky Muñoz, Miguel Cano, Felicity Cribbs
Publication Date: 2016-09-15
Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.
Authors: Shah, Nina R, Tancioni, Isabelle, Ward, Kristy K, Lawson, Christine, Chen, Xiao Lei, Jean, Christine, Sulzmaier, Florian J, Uryu, Sean, Miller, Nichol L G, Connolly, Denise C, Schlaepfer, David D
Journal: Gynecol Oncol
Publication Date: 2014-04-27
FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.
Authors: Isabelle Tancioni, Sean Uryu, Florian Sulzmaier, Nina Shah, Christine Lawson, Nichol L Miller, Christine Jean, Xiao Chen, Kristy Ward, David Schlaepfer
Publication Date: 2014-06-06
Lead Sponsor: AbbVie
Collaborators: Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Intervention / Treatment: DRUG: Paclitaxel, DRUG: Topotecan, DRUG: Mirvetuximab Soravtansine, DRUG: Pegylated liposomal doxorubicin
Lead Sponsor: ImmunoGen, Inc.
Intervention / Treatment: DRUG: Mirvetuximab Soravtansine
Lead Sponsor: NovoCure Ltd.
Intervention / Treatment: DRUG: Paclitaxel, DEVICE: NovoTTF-100L(O)